These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15295219)

  • 1. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
    Sáez-Llorens X; Moreno MT; Ramilo O; Sánchez PJ; Top FH; Connor EM;
    Pediatr Infect Dis J; 2004 Aug; 23(8):707-12. PubMed ID: 15295219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
    Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
    Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
    Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P; Trenholme A; Abarca K; Griffin MP; Hultquist M; Harris B; Losonsky GA;
    BMC Pediatr; 2010 Jun; 10():38. PubMed ID: 20525274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR; Nishida H
    Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C; Scott LJ; Plosker GL
    Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
    Boeckh M; Berrey MM; Bowden RA; Crawford SW; Balsley J; Corey L
    J Infect Dis; 2001 Aug; 184(3):350-4. PubMed ID: 11443562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
    Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha I; McKoy N
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palivizumab: where to from here?
    Georgescu G; Chemaly RF
    Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF; Cabalka AK; Meissner HC; Piazza FM; Carlin DA; Top FH; Connor EM; Sondheimer HM;
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha IJ
    Cochrane Database Syst Rev; 2014 May; (5):CD007743. PubMed ID: 24851825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy Adults.
    Aliprantis AO; Wolford D; Caro L; Maas BM; Ma H; Montgomery DL; Sterling LM; Hunt A; Cox KS; Vora KA; Roadcap BA; Railkar RA; Lee AW; Stoch SA; Lai E
    Clin Pharmacol Drug Dev; 2021 May; 10(5):556-566. PubMed ID: 33125189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.